Preclinical
Phase I
Phase IIa
Phase IIb
Phase III
Orismilast - Immunodermatology
Niclosamide - Infectious diseases
Other
*) Innovent Biologics has exclusive rights to oral orismilast and an option on topical orismilast for China, HK, Taiwan and Macau; UNION retains remaining worldwide rights.
**) Platform study sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and funded by LifeArc, Addenbrookes Charitable Trust, Kidney Research UK and UNION.
***) Worldwide rights out-licensed to Ceva.
Expanded access policy to be found here.